Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de fase 2/3 para avaliar a segurança e eficácia de EIK1001-006 em combinação com pembrolizumabe versus placebo e pembrolizumabe como terapia de primeira linha em pacientes com melanoma avançado

2 de outubro de 2026 atualizado por: Eikon Therapeutics

Um estudo multicêntrico, randomizado, duplo-cego, controlado por comparador ativo e adaptativo de fase 2/3 para avaliar a segurança e eficácia de EIK1001 e pembrolizumabe versus placebo e pembrolizumabe como terapia de primeira linha em participantes com melanoma avançado.

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Visão geral do estudo

Status

Recrutamento

Condições

Descrição detalhada

This is a Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma. The study includes dose optimization and expansion parts.

Tipo de estudo

Intervencional

Inscrição (Estimado)

740

Estágio

  • Fase 2
  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Krishna Kaza, Director Clinical Study Management
  • Número de telefone: +1 (516) 675-6163
  • E-mail: Kazak@eikontx.com

Locais de estudo

      • Dresden, Alemanha, 01307
        • Recrutamento
        • University Hospital Carl Gustav Carus Dresden
        • Contato:
        • Investigador principal:
          • Friedegund Meier
        • Subinvestigador:
          • Kathlen Hantsch
      • Erfurt, Alemanha, D-99089
      • Gera, Alemanha, 07548
        • Recrutamento
        • SRH Wald-Klinikum Gera GmbH
        • Investigador principal:
          • Sabine Sell
        • Contato:
        • Contato:
        • Subinvestigador:
          • Anne Meinzenbach
      • Münster, Alemanha, 48157
    • Baden-Wurttemberg
      • Mannheim, Baden-Wurttemberg, Alemanha, 68167
        • Recrutamento
        • Universitätsmedizin Mannheim
        • Investigador principal:
          • Jochen Utikal
        • Contato:
      • Tübingen, Baden-Wurttemberg, Alemanha, 72076
        • Recrutamento
        • Universitaetsklinikum Tuebingen (UKT)
        • Contato:
        • Investigador principal:
          • Andreas Meiwes
    • Bavaria
      • Würzburg, Bavaria, Alemanha, 97080
        • Recrutamento
        • Klinik für Dermatologie, Venerologie und Allergologie
        • Contato:
        • Contato:
          • Sandra Hupfloher
          • Número de telefone: +49 931 201 26762
          • E-mail: hasseli_s@ukw.de
        • Investigador principal:
          • Anja Gesierich
    • Erlangen
      • Erlangen, Erlangen, Alemanha, 91054
        • Recrutamento
        • University Hospital Erlangen
        • Contato:
        • Investigador principal:
          • Carola Berking
    • Free and Hanseatic City of Hamburg
      • Martinsried, Free and Hanseatic City of Hamburg, Alemanha, 20246
        • Recrutamento
        • Universitätsklinik Hamburg Eppendorf
        • Investigador principal:
          • Christoffer Gebhardt
        • Contato:
          • Christin Seeger
          • Número de telefone: +49 15222800599
          • E-mail: c.seeger@uke.de
    • Leipzig
    • Lower Saxony
    • North Rhine-Westphalia
      • Minden, North Rhine-Westphalia, Alemanha, 32429
        • Recrutamento
        • Johannes Wesling Klinikum Minden
        • Contato:
        • Investigador principal:
          • Ralf Gutzmer
    • RLP
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Alemanha, 24105
      • Lübeck, Schleswig-Holstein, Alemanha, 23538
        • Recrutamento
        • Universitätsklinikum Schleswig-Holstein - Campus Lübeck
        • Contato:
        • Contato:
        • Investigador principal:
          • Evelyn Gaffal
    • State of Berlin
      • Berlin, State of Berlin, Alemanha, 10115
        • Recrutamento
        • Charite Department of Dermatology, Venereology and Allergology
        • Investigador principal:
          • Thomas Eigentler
        • Contato:
    • New South Wales
    • Queensland
      • Chermside, Queensland, Austrália, 4032
        • Recrutamento
        • Icon Cancer Centre Chermside
        • Contato:
        • Contato:
        • Investigador principal:
          • Chun Gan
    • South Australia
      • Bedford Park, South Australia, Austrália, 5042
        • Recrutamento
        • Southern Adelaide Local Health Network Incorporated Flinders Medical Centre
        • Investigador principal:
          • Amitesh Roy
        • Contato:
        • Contato:
    • Victoria
      • Box Hill, Victoria, Austrália, 3128
        • Recrutamento
        • Eastern Health
        • Contato:
        • Investigador principal:
          • Phillip Parente
        • Subinvestigador:
          • Zhen R Siow
      • Frankston, Victoria, Austrália, 3199
        • Recrutamento
        • Peninsula and South Eastern Haematology and Oncology Group
        • Investigador principal:
          • Vinod Ganju
        • Contato:
          • Albert Goikhman
          • Número de telefone: +61 422510299
          • E-mail: ag@paso.com.au
      • Sint-Niklaas, Bélgica, 9100
        • Recrutamento
        • Vitaz Primary Location
        • Investigador principal:
          • Ines Deleu
        • Contato:
    • Antwerpen
      • Edegem, Antwerpen, Bélgica, 2650
        • Recrutamento
        • Universitair Ziekenhuis Antwerpen
        • Investigador principal:
          • Marika Rasschaert
        • Contato:
        • Contato:
        • Subinvestigador:
          • Timon Vandamme
    • Brussels Capital
      • Brussels, Brussels Capital, Bélgica, 1200
    • Namur
      • Yvoir, Namur, Bélgica, B-5530
        • Recrutamento
        • Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne
        • Contato:
        • Contato:
        • Investigador principal:
          • Laurence Faugeras
        • Subinvestigador:
          • Quentin Gilliaux
    • Vlaams Brabant
      • Leuven, Vlaams Brabant, Bélgica, 3000
        • Recrutamento
        • Universitair Ziekenhuis Leuven - Campus Gasthuisberg
        • Contato:
        • Contato:
        • Investigador principal:
          • Oliver Bechter
        • Subinvestigador:
          • Patrick Schöffski
    • West-Vlaanderen
      • Kortrijk, West-Vlaanderen, Bélgica, 8500
        • Recrutamento
        • Algemeen Ziekenhuis Groeninge - Campus Kennedylaan
        • Contato:
        • Contato:
        • Investigador principal:
          • Veronique Buyse
        • Subinvestigador:
          • Tine Loyson
    • Ontario
      • Toronto, Ontario, Canadá, M4N 3M5
        • Recrutamento
        • Sunnybrook Research Ins<tute
        • Investigador principal:
          • Rossanna Pezo
        • Contato:
        • Contato:
        • Subinvestigador:
          • Teresa Petrella
      • Daegu, Coréia do Sul, 41404
        • Recrutamento
        • Kyungpook National University Chilgok Hospital
        • Investigador principal:
          • Soo Jung Lee
        • Contato:
        • Subinvestigador:
          • In Hee Lee
      • Seoul, Coréia do Sul, 03080
        • Recrutamento
        • Seoul National University Hospital
        • Investigador principal:
          • Miso Kim
        • Contato:
        • Subinvestigador:
          • Seo Yoon Jang
    • Central Jutland
      • Aarhus, Central Jutland, Dinamarca, 8200
        • Suspenso
        • Aarhus Universitetshospital
    • Nord Jutland
      • Aalborg, Nord Jutland, Dinamarca, 9000
        • Suspenso
        • Aalborg University Hospital
      • Cadiz, Espanha, 11407
        • Recrutamento
        • University Hospital of Jerez
        • Contato:
        • Investigador principal:
          • Regina Garcia Galindo
        • Subinvestigador:
          • Gloria Aguilera
    • A Coruña
      • Santiago de Compostela, A Coruña, Espanha, 15706
        • Recrutamento
        • Hospital Clínico de Santiago de Compostela
        • Contato:
        • Investigador principal:
          • Teresa Curiel
        • Subinvestigador:
          • Alexandra Mosquera
    • Badalona
      • Badalona, Badalona, Espanha, 08916
        • Recrutamento
        • H. Germans Trias I Pujol (ICO-Badalona)
        • Contato:
        • Investigador principal:
          • José Manzano
    • Barcelona
      • Barcelona, Barcelona, Espanha, 08028
        • Recrutamento
        • Hospital Universitari Dexeus
        • Contato:
        • Contato:
        • Investigador principal:
          • Maria G Cao
        • Subinvestigador:
          • Josep S Ortega
      • Barcelona, Barcelona, Espanha, 08035
        • Recrutamento
        • Vall d' Hebron Institute of Oncology
        • Contato:
          • Alba Barrio
          • Número de telefone: 8827 (+34) 93 254 34 50
          • E-mail: bbruno@vhio.net
        • Contato:
          • Núria Llansana
          • Número de telefone: 5063 (+34) 93 254 3450
          • E-mail: nfarras@vhio.net
        • Investigador principal:
          • Eva M Couselo
    • Cantabria
      • Santander, Cantabria, Espanha, 39008
        • Recrutamento
        • Hospital Universitario Marques de Valdecilla
        • Investigador principal:
          • Marta García
        • Contato:
        • Subinvestigador:
          • Belen Caramelo
    • Cáceres
      • Cáceres, Cáceres, Espanha, 10003
    • Galicia
      • Lugo, Galicia, Espanha, 27003
        • Recrutamento
        • Hospital Universitario Lucus Augusti
        • Contato:
        • Investigador principal:
          • Begona Campos Balea
    • Girona
      • Girona, Girona, Espanha, 17007
        • Recrutamento
        • Institut Català d'Oncologia Girona (ICO Girona)
        • Contato:
        • Contato:
        • Subinvestigador:
          • Anna Carbó
        • Investigador principal:
          • Elisabet Bujons
    • Madrid
      • Madrid, Madrid, Espanha, 28007
        • Recrutamento
        • Hospital General Universitario Gregorio Marañón
        • Contato:
        • Investigador principal:
          • IVAN MARQUEZ
      • Madrid, Madrid, Espanha, 28002
        • Recrutamento
        • GenesisCare Madrid - Hospital San Francisco de Asís
        • Contato:
        • Investigador principal:
          • José Angel Garcia Cuesta
      • Madrid, Madrid, Espanha, 28050
        • Recrutamento
        • HM CIOCC
        • Contato:
        • Investigador principal:
          • Juan Rodriguez Moreno
      • Usera, Madrid, Espanha, 28031
        • Recrutamento
        • Hospital 12 de Octubre
        • Contato:
        • Investigador principal:
          • Guillermo De Velasco
    • Malaga
      • Málaga, Malaga, Espanha, 29011
        • Recrutamento
        • Hospital Regional Universitario
        • Contato:
        • Investigador principal:
          • Miguel Angel Berciano
    • Murcia
      • Murcia, Murcia, Espanha, 30120
        • Recrutamento
        • Hospital Clinico Universitario Virgen de la Arrixaca
        • Contato:
        • Investigador principal:
          • Pablo Fuentes
        • Subinvestigador:
          • Miguel Angel Moya
    • Málaga
      • Málaga, Málaga, Espanha, 29010
        • Recrutamento
        • Hospital Universitario Virgen de la Victoria
        • Contato:
        • Investigador principal:
          • Manuel Zalabardo
    • Spain
      • Barcelona, Spain, Espanha, 8036
        • Recrutamento
        • Hospital Clinic Barcelona
        • Contato:
        • Contato:
        • Investigador principal:
          • Ana Arance
        • Subinvestigador:
          • Maribel Marmol
    • Valencia
      • Valencia, Valencia, Espanha, 46009
        • Recrutamento
        • IVO - Fundacion Instituto Valenciano de Oncologia
        • Investigador principal:
          • Maria Jose Juan Fita
        • Contato:
        • Contato:
        • Subinvestigador:
          • Eduardo Nagore
      • Valencia, Valencia, Espanha, 46010
        • Recrutamento
        • INCLIVA Instituto de Investigación Sanitaria
        • Subinvestigador:
          • Valentina Gambardella
        • Contato:
        • Contato:
        • Investigador principal:
          • Ines G Barrallo
    • Arizona
      • Chandler, Arizona, Estados Unidos, 85224
        • Recrutamento
        • Ironwood Cancer & Research Centers
        • Contato:
        • Investigador principal:
          • Amikar Sehdev, MD
    • Arkansas
      • Hot Springs, Arkansas, Estados Unidos, 71913
        • Recrutamento
        • Genesis Cancer and Blood Institute
        • Investigador principal:
          • Robert Muldoon
        • Contato:
    • California
      • Los Angeles, California, Estados Unidos, 90015
      • Santa Rosa, California, Estados Unidos, 95403
        • Recrutamento
        • Providence Medical Foundation
        • Investigador principal:
          • David Park
        • Subinvestigador:
          • Natalie Valle
        • Contato:
    • Colorado
      • Colorado Springs, Colorado, Estados Unidos, 80909
        • Recrutamento
        • UCHealth Memorial Hospital Central
        • Contato:
        • Investigador principal:
          • Stacey ParkerBrueggemann, MD
    • Delaware
      • Newark, Delaware, Estados Unidos, 19713
    • Florida
      • Hialeah, Florida, Estados Unidos, 33013
      • Tamarac, Florida, Estados Unidos, 33321
        • Recrutamento
        • Florida Clinical Trials Group - Tamarac
        • Investigador principal:
          • Chintan Gandhi
        • Contato:
        • Contato:
        • Subinvestigador:
          • Lauren Brito
    • Maryland
      • Bethesda, Maryland, Estados Unidos, 20817
        • Recrutamento
        • The Center for Cancer and Blood Disorders
        • Investigador principal:
          • Victor Priego
        • Contato:
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64132
        • Recrutamento
        • MidAmerica Cancer Care
        • Investigador principal:
          • Jaswinder Singh
        • Contato:
      • St Louis, Missouri, Estados Unidos, 63108
        • Recrutamento
        • Washington University School of Medicine in St. Louis
        • Investigador principal:
          • George Ansstas
        • Contato:
        • Subinvestigador:
          • Nicole Chrisman
    • Ohio
      • Canton, Ohio, Estados Unidos, 44718
        • Recrutamento
        • Gabrail Cancer Center Research LLC
        • Investigador principal:
          • Nashat Gabrail
        • Contato:
        • Subinvestigador:
          • Carmen Baldwin
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • Recrutamento
        • University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center
        • Investigador principal:
          • Diwakar Davar, MD
        • Contato:
    • Texas
      • Sugar Land, Texas, Estados Unidos, 77479
        • Recrutamento
        • Patientcare Clinical Research
        • Investigador principal:
          • Amir Rasheed
        • Contato:
        • Subinvestigador:
          • Jianwen Dong
    • Oulu
      • Oulu, Oulu, Finlândia, 90230
        • Recrutamento
        • Oulu University Hospital
        • Contato:
        • Investigador principal:
          • Sanna Livanainen
    • Pirkanmaa
      • Tampere, Pirkanmaa, Finlândia, 33521
        • Recrutamento
        • Tampere University Hospital
        • Contato:
        • Investigador principal:
          • Tanja Skyttä
    • Uusimaa
      • Helsinki, Uusimaa, Finlândia, 00029
        • Recrutamento
        • Helsinki University Hospital
        • Contato:
        • Investigador principal:
          • Micaela Hernberg
      • Bordeaux, França, 33075
        • Recrutamento
        • Hospital Saint Andre
        • Contato:
        • Investigador principal:
          • Caroline Dutriaux
    • Auvergne-Rhône-Alpes
      • Pierre-Bénite, Auvergne-Rhône-Alpes, França, 69495
        • Recrutamento
        • Centre Hospitalier Lyon-Sud
        • Investigador principal:
          • Stéphane Dalle
        • Contato:
    • Boulogne
      • Boulogne, Boulogne, França, 92104
    • Isère
      • La Tronche, Isère, França, 38700
        • Recrutamento
        • Centre Hospitalier Universitaire Grenoble Alpes
        • Investigador principal:
          • Julie Charles
        • Contato:
    • Lille Cedex
      • Lille, Lille Cedex, França, 59037
    • Marseille
      • Marseille, Marseille, França, 13385
        • Recrutamento
        • Hôpital La Timone
        • Contato:
        • Investigador principal:
          • Caroline Gaudy
    • PACA
      • Nice, PACA, França, 06200
        • Recrutamento
        • Centre Hospitalier Universitaire (CHU) Nice
        • Contato:
        • Investigador principal:
          • Henri Montaudie
    • Paris
      • Paris, Paris, França, 75018
        • Recrutamento
        • Hôpital Bichat AP-HP Université Paris Cité
        • Contato:
        • Investigador principal:
          • Florence Brunet-Possenti
    • Pays de la Loire Region
      • Saint-Herblain, Pays de la Loire Region, França, 44800
    • Rouen
      • Rouen, Rouen, França, 76031
        • Recrutamento
        • CHU Rouen
        • Contato:
        • Investigador principal:
          • Anne Benedicte Duval Modeste
      • Pécs, Hungria, 7632
        • Recrutamento
        • University of Pécs
        • Contato:
        • Investigador principal:
          • Zsuzsanna Lengyel
    • Budapest
      • Budapest, Budapest, Hungria, 1122
        • Recrutamento
        • National Institute of Oncology
        • Contato:
        • Investigador principal:
          • Timea Balatoni
    • Be'er Sheva
      • Beersheba, Be'er Sheva, Israel, 8410101
        • Recrutamento
        • Soroka medical center
        • Contato:
        • Investigador principal:
          • Alexander Yakobson
    • Petach Tikva
      • Petah Tikva, Petach Tikva, Israel, 4941492
        • Recrutamento
        • Rabin Medical Center
        • Contato:
        • Investigador principal:
          • Nethanel Asher
    • Ramat Gan
      • Ramat Gan, Ramat Gan, Israel, 5262100
        • Recrutamento
        • Ella Lemelbaum Institute for Immuno-Oncology and Melanoma
        • Contato:
        • Investigador principal:
          • Ronnie Shapira-Frommer
        • Subinvestigador:
          • Raz Mutai
    • Tel Aviv
      • Tel Aviv, Tel Aviv, Israel, 6423906
        • Recrutamento
        • Tel Aviv Medical Center
        • Contato:
        • Investigador principal:
          • Mor Miodovnik
    • Foggia
      • San Giovanni Rotondo, Foggia, Itália, 71013
        • Recrutamento
        • Ospedale Casa Sollievo Della Sofferenza
        • Contato:
        • Contato:
        • Investigador principal:
          • Gabriele Di Maggio
        • Subinvestigador:
          • Antonella Centonza
    • Italy
      • Alessandria, Italy, Itália, 15121
        • Recrutamento
        • Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo
        • Investigador principal:
          • Federica Grosso
        • Contato:
        • Contato:
        • Subinvestigador:
          • Delfanti Sara
      • Messina, Italy, Itália, 98039
        • Recrutamento
        • Ospedale San Vincenzo Taormina
        • Contato:
        • Contato:
        • Investigador principal:
          • Francesco Ferraù
        • Subinvestigador:
          • Elena Torrisi
      • Milan, Italy, Itália, 20133
      • Modena, Italy, Itália, 41125
        • Recrutamento
        • AOU Policlinico di Modena
        • Contato:
        • Contato:
        • Investigador principal:
          • Roberta Depenni
        • Subinvestigador:
          • Stefano Greco
      • Padova, Italy, Itália, 35128
        • Recrutamento
        • Istituto Oncologico Veneto IRCCS
        • Contato:
        • Contato:
        • Investigador principal:
          • Jacopo Pigozzo
        • Subinvestigador:
          • Luisa Piccin
      • Trento, Italy, Itália, 38123
        • Recrutamento
        • Azienda Provinciale per I Servizi Sanitari
        • Contato:
        • Contato:
        • Investigador principal:
          • Sonia Brugnara
        • Subinvestigador:
          • Federico Sganzerla
    • Liguria
      • Genoa, Liguria, Itália, 16132
        • Recrutamento
        • IRCCS Ospedale Policlinico San Marino
        • Contato:
        • Contato:
        • Investigador principal:
          • Francesco Spagnolo
        • Subinvestigador:
          • Andrea Boutros
    • Milano
      • Milan, Milano, Itália, 20132
        • Recrutamento
        • IRCCS Ospedale San Raffaele
        • Contato:
        • Investigador principal:
          • Vincenzo Russo
    • Province of Bergamo
      • Bergamo, Province of Bergamo, Itália, 24125
        • Recrutamento
        • Humanitas Gavazzeni Bergamo
        • Contato:
        • Investigador principal:
          • Laura Pala
    • The Marches
      • Ancona, The Marches, Itália, 60126
    • Tuscany
      • Siena, Tuscany, Itália, 53100
        • Recrutamento
        • UOC Immunoterapia Oncologica
        • Contato:
        • Investigador principal:
          • Anna Maria Di Giacomo
    • Bodø
      • Bodø, Bodø, Noruega, N-8005
        • Recrutamento
        • Nordland Hospital Trust
        • Contato:
        • Investigador principal:
          • Bard Mannsaker
    • Oslo
      • Oslo, Oslo, Noruega, 0310
        • Recrutamento
        • Oslo University Hospital - The Norwegian Radium Hospital
        • Contato:
        • Investigador principal:
          • Marta Nyakas
    • Oslofjord
      • Drammen, Oslofjord, Noruega, 3004
        • Recrutamento
        • Drammen Hospital
        • Contato:
        • Subinvestigador:
          • Alina Carmen Porojnicu
    • Christchurch
      • Christchurch, Christchurch, Nova Zelândia, 8011
        • Recrutamento
        • Christchurch Public Hospital
        • Contato:
        • Investigador principal:
          • David Gibbs
    • New Zealand
      • Auckland, New Zealand, Nova Zelândia, 1023
        • Recrutamento
        • Auckland City Hospital
        • Contato:
        • Contato:
        • Investigador principal:
          • Gareth Rivalland, MD
    • Gdańsk
      • Gdansk, Gdańsk, Polônia, 80-952
        • Recrutamento
        • Uniwersyteckie Centrum Kliniczne
        • Contato:
        • Investigador principal:
          • Kamil Drucis
    • Konin
      • Konin, Konin, Polônia, 62-500
        • Recrutamento
        • Prezychodnia Lekarska KOMED Roman Karaszewski
        • Investigador principal:
          • Bogusława Karaszewska
        • Contato:
    • Siedlce
      • Siedlce, Siedlce, Polônia, 08-110
        • Recrutamento
        • Mazowiecki Szpital Wojewódzki, Siedlckie Centrum Onkologii
        • Investigador principal:
          • Lubomir Bodnar
        • Contato:
    • Silesian Voivodeship
      • Gliwice, Silesian Voivodeship, Polônia, 44-102
        • Recrutamento
        • Maria Sklodowska-Curie Na;onal Research Ins;tute of Oncology, Gliwice Branch
        • Investigador principal:
          • Wieslaw Bal
        • Contato:
        • Contato:
        • Subinvestigador:
          • Anna Kotas
    • Warsaw
      • Warsaw, Warsaw, Polônia, 02-781
        • Recrutamento
        • Maria Sklodowska-Curie National Cancer Research Institute
        • Contato:
        • Investigador principal:
          • Anna Czarnecka
    • Lisbon District
      • Lisbon, Lisbon District, Portugal, 1500-650
        • Recrutamento
        • Hospital da Luz Lisboa
        • Contato:
        • Contato:
        • Investigador principal:
          • Gonçalo Fernandes
      • Lisbon, Lisbon District, Portugal, 1099-023
        • Recrutamento
        • IPO Lisboa
        • Contato:
        • Investigador principal:
          • Patricia Pereira
    • Belfast
      • Belfast, Belfast, Reino Unido, BT9 7AB
        • Recrutamento
        • Belfast City Hospital, Belfast Health and Social Care Trust
        • Contato:
        • Investigador principal:
          • Bode Oladipo
    • England
      • London, England, Reino Unido, SE1 9RT
        • Recrutamento
        • Guy's and St Thomas' NHS Foundation Trust
        • Contato:
        • Contato:
        • Investigador principal:
          • Alvin Lee
      • London, England, Reino Unido, W1G6AD
        • Recrutamento
        • Sarah Cannon Research Institute London
        • Investigador principal:
          • Anja Williams
        • Contato:
        • Subinvestigador:
          • Elisa Fontana
    • Hampshire
      • Southampton, Hampshire, Reino Unido, SO32 2DA
        • Recrutamento
        • University Hospital Southampton
        • Contato:
        • Investigador principal:
          • Matthew Wheater
    • Gävleborg County
      • Gävle, Gävleborg County, Suécia, 801 88
        • Recrutamento
        • Gävle Sjukhus
        • Contato:
        • Investigador principal:
          • Ilke Cikman
        • Subinvestigador:
          • Olga Del Val Munoz
    • Södermanland County
      • Stockholm, Södermanland County, Suécia, 17176
        • Recrutamento
        • Karolinska University Hospital
        • Contato:
        • Investigador principal:
          • Hannah Eriksson
    • Canton of Zurich
      • Zurich, Canton of Zurich, Suíça, 8091
        • Recrutamento
        • Universitätsspital Zürich
        • Investigador principal:
          • Egle Ramelyte
        • Contato:
        • Contato:
        • Subinvestigador:
          • Michele Welti
    • Chur
      • Chur, Chur, Suíça, 7000
        • Recrutamento
        • Kantonsspital Graubünden
        • Contato:
        • Investigador principal:
          • Roger von Moos
    • Belgrade
      • Belgrade, Belgrade, Sérvia, 11000
        • Recrutamento
        • Military Medical Academy- Department of Oncology
        • Contato:
        • Investigador principal:
          • Lidija Kandolf
    • Brno
      • Brno, Brno, Tcheca, 65653
        • Recrutamento
        • Masaryk Memorial Cancer Institute
        • Contato:
        • Investigador principal:
          • Radek Lakomy
        • Subinvestigador:
          • Svatopluk Dobeš
    • Hradce Kralove
      • Sokolov, Hradce Kralove, Tcheca, 50009
        • Recrutamento
        • University Hospital Hradec Kralove
        • Investigador principal:
          • Jindrich Kopecky
        • Contato:
    • Eastern Cape
      • Port Elizabeth, Eastern Cape, África do Sul, 6045
        • Recrutamento
        • Cancercare Port Elizabeth - Langenhoven Drive Oncology Centre
        • Contato:
        • Investigador principal:
          • John Crockett
        • Subinvestigador:
          • Sakina Bawa
    • Gauteng
      • Pretoria, Gauteng, África do Sul, 0002
        • Recrutamento
        • University of Pretoria, Steve Biko Academic Hospital
        • Investigador principal:
          • Richard Khanyile
        • Contato:
      • Saxonwold, Gauteng, África do Sul, 2196
        • Recrutamento
        • The Medical Oncology Centre of Rosebank
        • Contato:
        • Investigador principal:
          • Bernardo Rapoport
    • KwaZulu-Natal
      • Richards Bay, KwaZulu-Natal, África do Sul, 3900
        • Recrutamento
        • Abraham Oncology
        • Investigador principal:
          • Smitha Abraham
        • Contato:
    • Pretoria
      • Pretoria, Pretoria, África do Sul, 0084
        • Recrutamento
        • Curo Oncology
        • Contato:
        • Investigador principal:
          • Rouchelle Marais-Nieman
    • Western Cape
      • Cape Town, Western Cape, África do Sul, 7570
        • Recrutamento
        • Cape Town Oncology Trials
        • Investigador principal:
          • Corlia Coetzee
        • Contato:
        • Contato:
        • Subinvestigador:
          • Johann Riedemann
      • George, Western Cape, África do Sul, 6529
        • Recrutamento
        • TASK Eden
        • Contato:
        • Contato:
        • Investigador principal:
          • Louis Botha
        • Subinvestigador:
          • Alista Easton
    • Styria
      • Graz, Styria, Áustria, 8036
        • Recrutamento
        • Universitätsklinikum Graz
        • Contato:
        • Investigador principal:
          • Ingrid Wolf
        • Subinvestigador:
          • Christiane Mutz-Rabl

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

To be eligible for inclusion in this study, participants must:

  • Be ≥ 18 years of age on the day of signing of informed consent.
  • Have a life expectancy of at least 3 months.
  • Have histologically or cytologically confirmed Stage 3 (unresectable) or Stage 4 metastatic melanoma per AJCC 8th ed. and be eligible for standard therapy with pembrolizumab.
  • Have at least 1 lesion with measurable disease at Baseline by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by assessment of local site Investigator/radiologist.
  • Have known BRAF V600 mutation status or consent to BRAF V600 mutation testing per local institutional standards during the screening period
  • Have completed prior radiotherapy at least 2 weeks prior to study treatment administration.
  • Have an ECOG Performance Status of 0 to 1.
  • Have adequate organ and marrow function as defined by normal CBC, coagulation, serum chemistry and liver function tests on specimens collected within 10 days of treatment start.
  • Have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication (applies to women of childbearing potential [WOCBP]).
  • Be willing to use either 2 adequate methods of contraception, 1 adequate method plus a hormonal method of contraception, or be willing to abstain from heterosexual activity throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to WOCBP who are not menopausal for > 2 years, post-hysterectomy/oophorectomy, or surgically sterilized).
  • Agree to use an approved adequate contraceptive method throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to sexually active male participants with a partner who is WOCBP).
  • Be willing and able to provide written, informed consent for the study.

Exclusion Criteria:

A participant is excluded from the study if any of the following criteria apply:

  • Has melanoma of ocular origin.
  • Is currently enrolled in or has recently participated in a study of an IMP and received an IMP within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001 or placebo.
  • Prior to the 1St dose of EIK1001 or placebo, the prospective participant has received systemic therapy for advanced melanoma.
  • Note: prior adjuvant or neoadjuvant melanoma therapies (such as anti-PD-1 or anti CTLA 4 therapies or BRAF/MEK inhibitors) are permitted if all related AEs have either returned to Baseline or stabilized, with a minimum of 6 months between the last dose of prior therapy and documented disease progression.
  • Experienced a ≥ Grade 3 AE while receiving prior anti PD 1 therapy.
  • Has had major surgery (< 3 weeks prior to the first dose).
  • Has received a live-virus vaccination within 30 days of the first dose of study treatment.
  • Has a known history of prior malignancy, unless the participant has undergone potentially curative therapy with no evidence of disease recurrence for 5 years.
  • Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate if they are clinically stable for at least 4 weeks with no evidence of new or enlarging brain metastases. There must be no need for immunosuppressive doses of glucocorticoids for at least 2 weeks prior to study treatment administration.
  • There is a mean resting QTcF > 470 ms on triplicate electrocardiograms.
  • There is active autoimmune disease that has required systemic treatment in the past 2 years. The following autoimmune conditions are permitted: Type 1 diabetes, hypothyroidism (on hormone replacement), or- vitiligo, psoriasis and alopecia as long as no systemic treatment is required.
  • There is either chronic treatment with systemic steroids, other immunosuppressive medication, or either of these has been administered within 14 days of start of study treatment.
  • Note: Participants with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections are eligible. Steroid replacement for adrenal insufficiency is also permitted.
  • There is a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/ interstitial lung disease.
  • There are any active infections requiring therapy.
  • There is uncontrolled human immunodeficiency virus (HIV) infection. HIV-infected participants with well-controlled HIV may enroll.
  • There is a positive test result for hepatitis B virus (HBV) or HCV indicating presence of virus (it is expected that all participants will have been serologically tested for hepatitis B in advance of this study, with HBsAG, anti-HBc IgG, and anti-HBs as per ASCO 2020 Provisional Clinical Opinion [PCO] on universal Serologic testing for hepatitis B at the onset of anticancer therapy; screening should also include an anti-HCV test prior to start of cancer treatment:
  • There is a history or clinical evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with the participant's participation for the full duration of the study
  • Known psychiatric or substance abuse disorder that would interfere with cooperation with study requirements.
  • There is a known history of regular illicit drug use and/or recent history (within the last year) of substance abuse (including alcohol).
  • Participant is pregnant, breastfeeding, or planning to conceive or father children within the projected duration of the study.
  • Participant is currently receiving medications known to be strong inhibitors or inducers of CYP3A4 and CYP1A2.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Arm 1

Participants in this arm will receive Placebo and Standard of Care (Pembrolizumab).

Pembrolizumab is a PD-1 inhibitor.

Experimental: Arm 2

Participants in this arm will receive EIK1001 (selected dose 1) + Standard of Care (Pembrolizumab).

Pembrolizumab is a PD-1 inhibitor.

EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.

Experimental: Arm 3

Participants in this arm will receive EIK1001 (selected dose 2) + Standard of Care (Pembrolizumab).

Pembrolizumab is a PD-1 inhibitor.

EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Progression Free Survival (PFS)
Prazo: up to 5 years

Progression-free survival (PFS) is defined as the time from the date of randomization to documented progressive disease per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.

up to 5 years
Overall survival (OS)
Prazo: up to 5 years

Overall survival (OS) defined as the time from randomization to death due to any cause.

up to 5 years
Objective Response (OR) (Dose Optimization Only)
Prazo: up to 5 years

Objective Response (OR; defined as participants who demonstrate confirmed complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator) (Dose Optimization Only).

up to 5 years
Adverse Events (AEs) (Dose Optimization Only)
Prazo: up to 2.5 years

Adverse events (AEs), and discontinuation of study treatment due to an AE (Dose Optimization Only). An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

up to 2.5 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Adverse Events (AEs) and Discontinuation of study treatment due to any AE.
Prazo: up to 2.5 years

Adverse events (AEs), and discontinuation of study treatment due to any AE. An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

up to 2.5 years
Objective Response (OR)
Prazo: up to 5 years

Objective response (OR) is defined as the participants who demonstrate confirmed response (CR) or partial response (PR) according to RECIST 1.1 by BICR.

up to 5 years
Duration of Response (DOR).
Prazo: up to 5 years

Duration of Response (DOR) is defined as the time from the first documented evidence of complete response (CR) or partial response (PR) until disease progression or death due to any cause, whichever occurs first according to RECIST 1.1 by BICR.

up to 5 years
Progression Free Survival (PFS)
Prazo: up to 5 years

Progression Free Survival (PFS) according to RECIST 1.1 by Investigator.

up to 5 years
Objective Response (OR)
Prazo: up to 5 years

Objective Response (OR) according to RECIST 1.1 by Investigator.

up to 5 years
Duration of Response (DOR)
Prazo: up to 5 years

Duration of Response (DOR) according to RECIST 1.1 by Investigator

up to 5 years
Duration of Response (DOR) (Dose Optimization Only).
Prazo: up to 5 years

Duration of Response (DOR) per RECIST 1.1 by Investigator (Dose Optimization Only).

up to 5 years
Progression-free survival (PFS) per RECIST 1.1 by Investigator (Dose Optimization Only).
Prazo: up to 5 years

Progression-free survival (PFS) per RECIST 1.1 by Investigator (Dose Optimization Only).

up to 5 years
Overall survival (OS) (Dose Optimization Only)
Prazo: up to 5 years

Overall survival (OS) defined as the time from randomization to death due to any cause (Dose Optimization Only).

up to 5 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Diretor de estudo: Etah Kurland, Eikon Therapeutics
  • Diretor de estudo: Muaz Sadeia, Eikon Therapeutics

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

22 de maio de 2025

Conclusão Primária (Estimado)

1 de dezembro de 2035

Conclusão do estudo (Estimado)

1 de dezembro de 2040

Datas de inscrição no estudo

Enviado pela primeira vez

18 de novembro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de novembro de 2024

Primeira postagem (Real)

20 de novembro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de outubro de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • EIK1001-006
  • KEYNOTE-G04 (Outro identificador: Merck Sharp & Dohme LLC)
  • MK-3475-G04 (Outro identificador: Merck Sharp & Dohme LLC)

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever